Aclaris director reports equity awards and RSU vesting

Aclaris Therapeutics director Christopher P. Molineaux reported routine equity compensation activity.

Accepted by SEC EDGAR 06/08/2026 - 04:15 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Aclaris Therapeutics director Christopher P. Molineaux reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and 42,350 stock options with an exercise price of $4.71 per share. On June 5, 2026, 11,580 previously granted RSUs vested and converted into common stock, bringing his direct common share holdings to 69,536.

Insider Trade Summary

11,580 shares exercised/converted

Exercise 4 txns

Insider Molineaux Christopher P.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	11,580	$0.00	$0.00
Exercise	Common Stock	11,580	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	42,350	$0.00	$0.00
Grant/Award	Restricted Stock Units	10,987	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 42,350 contracts (Direct); Restricted Stock Units — 10,987 contracts (Direct); Common Stock — 69,536 shares (Direct)

Footnotes (5)

F1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F5. The shares underlying these restricted stock units vested on June 5, 2026.

Key Figures

RSUs vested and converted: 11,580 shares Common shares held after transactions: 69,536 shares New RSU grant: 10,987 units +3 more

6 metrics

RSUs vested and converted 11,580 shares Previously granted restricted stock units vested on June 5, 2026

Common shares held after transactions 69,536 shares Direct Aclaris common stock ownership after June 5, 2026 vesting

New RSU grant 10,987 units Restricted stock units granted June 4, 2026, vesting June 4, 2027

Stock options granted 42,350 options Options on common stock granted June 4, 2026

Option exercise price $4.71 per share Exercise price for 42,350 stock options expiring June 3, 2036

Equity transactions direction 4 acquisitions All Form 4 entries are acquisitions/awards, no sales reported

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), Continuous Service, 2025 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Units financial

"The shares underlying these restricted stock units vested on June 5, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) covering 42,350 shares of common stock."

Continuous Service financial

"subject to the Reporting Person's Continuous Service through each such vesting date."

2025 Equity Incentive Plan financial

"as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan."

non-employee director compensation policy financial

"This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Aclaris Therapeutics (ACRS) director Christopher P. Molineaux report?

Christopher P. Molineaux reported equity compensation transactions, including new grants of restricted stock units and stock options, plus the vesting and conversion of previously granted RSUs into common stock. These are routine compensation-related awards, not open-market purchases or sales.

How many ACRS shares does Christopher P. Molineaux hold after these Form 4 transactions?

After the reported transactions, Christopher P. Molineaux directly holds 69,536 shares of Aclaris Therapeutics common stock. This reflects the 11,580 restricted stock units that vested and converted into common shares on June 5, 2026, increasing his direct ownership.

What restricted stock unit awards did ACRS director Christopher P. Molineaux receive?

On June 4, 2026, Christopher P. Molineaux received 10,987 restricted stock units, each representing a right to one Aclaris common share. These RSUs are scheduled to vest in a single installment on June 4, 2027, subject to his continuous service with the company.

What stock options were granted to Christopher P. Molineaux by Aclaris Therapeutics (ACRS)?

Christopher P. Molineaux was granted stock options covering 42,350 Aclaris common shares at an exercise price of $4.71 per share. These options were granted under the company’s 2025 Equity Incentive Plan and vest in twelve equal monthly installments starting July 4, 2026.

Were Christopher P. Molineaux’s ACRS insider transactions open-market buys or sells?

The reported transactions were not open-market buys or sells. They reflect equity compensation: grants of restricted stock units and stock options, plus the vesting and conversion of previously awarded RSUs into common stock, all recorded with no purchase or sale price per share.

When did Christopher P. Molineaux’s previously granted ACRS restricted stock units vest?

Previously granted restricted stock units underlying 11,580 Aclaris common shares vested on June 5, 2026. Upon vesting, they converted into an equal number of common shares, increasing Christopher P. Molineaux’s direct holdings to 69,536 shares of Aclaris common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Molineaux Christopher P.

(Last)

(First)

(Middle)

C/O ACLARIS THERAPEUTICS, INC.

701 LEE ROAD, SUITE 103

(Street)

WAYNE

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aclaris Therapeutics, Inc. [ ACRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/05/2026		M		11,580	A	⁽¹⁾	69,536	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.71	06/04/2026		A		42,350		⁽²⁾	06/03/2036	Common Stock	42,350	$0	42,350⁽³⁾	D
Restricted Stock Units	⁽¹⁾	06/04/2026		A		10,987		⁽⁴⁾	⁽⁴⁾	Common Stock	10,987	$0	10,987⁽³⁾	D
Restricted Stock Units	⁽¹⁾	06/05/2026		M			11,580	⁽⁵⁾	⁽⁵⁾	Common Stock	11,580	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

2. The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.

3. This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

4. The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.

5. The shares underlying these restricted stock units vested on June 5, 2026.

	/s/ Matthew Rothman, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR